ChromaDex (CDXC) announced the appointment of Ozan Pamir as CFO. Pamir will oversee all ChromaDex corporate finance matters, including accounting, strategic financial planning, and engaging with public markets through investor relations. Effective October 21, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru Niagen. Prior to joining ChromaDex, Ozan Pamir most recently served as CFO of 180 Life Sciences (ATNF).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDXC:
- ChromaDex expands pharmaceutical-grade Niagen IV, injection offerings
- ChromaDex broadens NAD+ precursor intellectual property portfolio with patent
- ChromaDex management to meet virtually with Roth MKM
- Chromadex Shares Insightful Corporate Presentation Update
- ChromaDex sees FY24 revenue growth 10%-15%
Questions or Comments about the article? Write to editor@tipranks.com